Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SmithKline Beecham's Paxil

Executive Summary

Supplemental NDA for generalized anxiety disorder is filed April 28. The company says that paroxetine is the first selective serotonin reuptake inhibitor submitted to the FDA for the treatment of GAD, which affects an estimated 14 mil. Americans. The condition is characterized by exaggerated tension and worry that interfere with daily function for at least six months

You may also be interested in...

Paxil Generalized Anxiety Relapse Prevention Data To Be Presented At APA

GlaxoSmithKline will present results from a 32-week study of Paxil in relapse prevention of generalized anxiety disorder at the American Psychiatric Association annual meeting in New Orleans May 5-10.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts